男性乳腺癌内分泌治疗疗效:MALE 2期随机临床试验结果
这项多中心2期随机临床试验纳入56例激素受体阳性男性乳腺癌患者,随机接受他莫昔芬单药、他莫昔芬联合GnRHa或AI联合GnRHa治疗6个月。主要终点为3个月时雌二醇水平变化,结果显示联合GnRHa组雌二醇持续下降,但性功能和生活质量也下降。
要点
- 他莫昔芬单药3个月雌二醇中位升高67%(+17.0 ng/L)。
- 他莫昔芬联合GnRHa或AI联合GnRHa使雌二醇持续下降。
- 加用GnRHa后性功能和生活质量下降。
核心结论
- AI或他莫昔芬联合GnRHa较他莫昔芬单药可导致雌二醇水平持续下降。
- 激素参数下降与性功能和生活质量受损相关。
研究设计与样本
- 多中心2期随机临床试验,评估56例激素受体阳性男性乳腺癌患者。
- 随机分为他莫昔芬单药、他莫昔芬联合GnRHa或AI联合GnRHa治疗6个月。
主要发现
- 3个月时他莫昔芬组雌二醇中位升高67%(+17.0 ng/L),他莫昔芬联合GnRHa组降低85%(-23.0 ng/L),AI联合GnRHa组降低72%(-18.5 ng/L),P < .001。
- 6个月时他莫昔芬组雌二醇中位升高41%(+12 ng/L),他莫昔芬联合GnRHa组降低61%(-19.5 ng/L),AI联合GnRHa组降低64%(-17.0 ng/L),P < .001。
- 加用GnRHa后性功能和生活质量下降,他莫昔芬单药组无变化。
临床怎么用
- 对于激素受体阳性男性乳腺癌,需权衡联合GnRHa带来的雌二醇下降与性功能及生活质量受损。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The extent of changes in estradiol levels in male patients with hormone receptor-positive breast cancer receiving standard endocrine therapies is unknown. The sexual function and quality of life related to those changes have not been adequately evaluated. OBJECTIVE: To assess the changes in estradiol levels in male patients with breast cancer after 3 months of therapy. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 2 randomized clinical trial assessed 56 male patients with hormone receptor-positive breast cancer. Patients were recruited from 24 breast units across Germany between October 2012 and May 2017. The last patient completed 6 months of treatment in December 2017. The analysis data set was locked on August 24, 2018, and analysis was completed on December 19, 2018. INTERVENTIONS: Patients were randomized to 1 of 3 arms: tamoxifen alone or tamoxifen plus gonadotropin-releasing hormone analogue (GnRHa) or aromatase inhibitor (AI) plus GnRHa for 6 months. MAIN OUTCOMES AND MEASURES: The primary end point was the change in estradiol levels from baseline to 3 months. Secondary end points were changes of estradiol levels after 6 months, changes of additional hormonal parameters, adverse effects, sexual function, and quality of life after 3 and 6 months. RESULTS: In this phase 2 randomized clinical trial, a total of 52 of 56 male patients with a median (range) age of 61.5 (37-83) years started treatment. A total of 3 patients discontinued study treatment prematurely, 1 in each arm. A total of 50 patients were evaluable for the primary end point. After 3 months the patients' median estradiol levels increased by 67% (a change of +17.0 ng/L) with tamoxifen, decreased by 85% (-23.0 ng/L) with tamoxifen plus GnRHa, and decreased by 72% (-18.5 ng/L) with AI plus GnRHa (P < .001). After 6 months, median estradiol levels increased by 41% (a change of +12 ng/L) with tamoxifen, decreased by 61% (-19.5 ng/L) with tamoxifen plus GnRHa, and decreased by 64% (-17.0 ng/L) with AI plus GnRHa (P < .001). Sexual function and quality of life decreased when GnRHa was added but were unchanged with tamoxifen alone. CONCLUSIONS AND RELEVANCE: This phase 2 randomized clinical trial found that AI or tamoxifen plus GnRHa vs tamoxifen alone led to a sustained decrease of estradiol levels. The decreased hormonal parameters were associated with impaired sexual function and quality of life. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01638247.
引用
- Reinisch M, Seiler S, Hauzenberger T, et al. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33538790. doi:10.1001/jamaoncol.2020.7442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。